You are here

Home

Clinical Trials: Central Nervous System Diseases

Each Clinical Trial will open in a new browser window or tab.

Return to Clinical Trials Page

Posted: Tuesday, March 23, 2021 - 12:00
Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke
Condition:   Ischemic Stroke
Interventions:   Biological: Umbilical Cord-derived Mesenchymal Stem Cells;   Drug: Placebo
Sponsor:   General Hospital of Shenyang Military Region
Recruiting
Posted: Tuesday, March 23, 2021 - 12:00
Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI
Conditions:   Spinal Cord Injury, Acute;   Spinal Cord Injury at C4 Level With Complete Lesion;   Spinal Cord Injury at C5-C7 Level With Complete Lesion
Intervention:   Biological: Neural precursor cells derived from human embryonic stem cell line
Sponsors:   S.Biomedics Co., Ltd.;   Linical Co., Ltd.;   Yonsei University
Not yet recruiting
Posted: Tuesday, February 9, 2021 - 12:00
Evaluatiton the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS
Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Biological: Lenzumestrocel;   Drug: Riluzole
Sponsor:   Corestem, Inc.
Recruiting
Posted: Thursday, December 3, 2020 - 12:00
The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS
Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Drug: Mesenchymal stem cells isolated from Wharton's jelly
Sponsors:   Polski Bank Komorek Macierzystych JSC (PBKM);   The National Centre for Research and Development
Recruiting
Posted: Tuesday, November 17, 2020 - 12:00
A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)
Condition:   Ischemic Stroke
Intervention:   Biological: Neural Stem Cells
Sponsor:   Gary Steinberg
Not yet recruiting
Posted: Thursday, October 29, 2020 - 12:00
A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogenic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)
Condition:   Acute Ischemic Stroke
Interventions:   Biological: JTR-161;   Biological: Placebo
Sponsor:   Teijin Pharma Limited
Recruiting
Posted: Monday, October 19, 2020 - 12:00
Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)
Condition:   Ischemic Stroke
Interventions:   Drug: it-hMSC;   Drug: Placebo
Sponsors:   Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.;   Beijing Tiantan Hospital
Not yet recruiting
Posted: Thursday, August 27, 2020 - 12:00
Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury
Condition:   Spinal Cord Injury
Interventions:   Biological: Autologous bone marrow-derived mononuclear cells;   Drug: Placebo
Sponsor:   Shanghai Changzheng Hospital
Not yet recruiting
Posted: Thursday, August 20, 2020 - 12:00
Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients
Conditions:   Spinal Cord Injuries;   Paralysis
Interventions:   Other: Best Medical Management: Occupational and Physical Therapy;   Biological: Autologous, Adipose Derived Mesenchymal Stem Cells
Sponsor:   Allan Dietz
Recruiting
Posted: Monday, August 10, 2020 - 12:00
Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD
Condition:   Parkinson's Disease
Interventions:   Drug: MSC+placebo;   Drug: MSC;   Drug: Placebo
Sponsors:   The University of Texas Health Science Center, Houston;   Michael J. Fox Foundation for Parkinson's Research
Not yet recruiting

Pages